HGBL with MYC and BCL2 and/or BCL6 rearrangements
Clinical trials for HGBL with MYC and BCL2 and/or BCL6 rearrangements explained in plain language.
Never miss a new study
Get alerted when new HGBL with MYC and BCL2 and/or BCL6 rearrangements trials appear
Sign up with your email to follow new studies for HGBL with MYC and BCL2 and/or BCL6 rearrangements, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
A CAR-T therapy given by injection: can it help Hard-to-Treat lymphoma?
Cure Recruiting nowResearchers are testing a new CAR-T cell therapy called C402-CD19-CAR in adults with large B-cell lymphoma that has come back or stopped responding to treatment. The therapy is made from each participant's own T cells, which are modified to target CD19, a marker on lymphoma cells…
Matched conditions: HGBL WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase 1 • Sponsor: Shanghai Exuma Biotechnology Ltd. • Aim: Cure
Last updated Sep 13, 2026 00:00 UTC
-
New CAR T-Cell therapy SynKIR-310 enters first human trial for Tough-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…
Matched conditions: HGBL WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase 1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC